Home > Boards > US Listed > Biotechs > Aquestive Therapeutics Inc (AQST)

Aquestive backs FY19 revenue $38M-$45M, consensus $42.82M Aquestive

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ADVFN_bioking Member Profile
 
Followed By 26
Posts 630
Boards Moderated 8
Alias Born 05/15/17
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:03:18 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 4:35:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/10/2020 7:05:56 AM
Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Liberv... GlobeNewswire Inc. - 2/10/2020 7:00:10 AM
Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemi... GlobeNewswire Inc. - 2/6/2020 7:00:10 AM
Aquestive Therapeutics Receives FDA Response to Citizen’s Petition GlobeNewswire Inc. - 1/12/2020 6:16:59 PM
Aquestive Therapeutics Exceeds Top End of Guidance Range for Preliminary Unaudited Full Year 2019 Total Revenues and Provide... GlobeNewswire Inc. - 1/10/2020 6:30:10 AM
Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire Inc. - 12/12/2019 8:00:10 PM
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire Inc. - 12/10/2019 4:01:10 PM
Aquestive Therapeutics to Host Investor & Analyst Libervant™ (diazepam) Buccal Film Update Forum at American Epilepsy Socie... GlobeNewswire Inc. - 12/4/2019 8:30:10 AM
Aquestive Therapeutics Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) ... GlobeNewswire Inc. - 12/2/2019 7:30:10 AM
Aquestive Therapeutics Announces Poster Presentations of Data on Libervant™ (diazepam) Buccal Film at American Epilepsy Soc... GlobeNewswire Inc. - 11/26/2019 11:27:11 AM
Aquestive Therapeutics Receives FDA Approval for Exservan™ (riluzole) Oral Film GlobeNewswire Inc. - 11/25/2019 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/13/2019 8:49:22 AM
Aquestive Therapeutics Licenses Riluzole Oral Film to Zambon for Development and Commercialization in the EU for Patients wit... GlobeNewswire Inc. - 11/13/2019 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 5:29:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 5:03:29 PM
Aquestive Therapeutics Reports Third Quarter 2019 Financial Results and Raises 2019 Guidance GlobeNewswire Inc. - 11/5/2019 4:50:44 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/16/2019 6:01:51 AM
Aquestive Therapeutics Reaffirms Full Year 2019 Revenue Guidance and Will Announce Third Quarter 2019 Financial Results and R... GlobeNewswire Inc. - 10/15/2019 5:41:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:34:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:34:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/30/2019 7:01:02 AM
Aquestive Therapeutics Announces Successful Completion of Phase 1 Trial for AQST-108 (Sublingual Film Formulation Delivering... GlobeNewswire Inc. - 9/30/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/20/2019 4:30:59 PM
ADVFN_bioking   Wednesday, 10/16/19 09:12:59 AM
Re: None
Post # of 70 
Aquestive backs FY19 revenue $38M-$45M, consensus $42.82M Aquestive Therapeutics announced, in response to Indivior PLC's press release issued earlier today of Indivior's intent to cease production of its authorized generic buprenorphine-naloxone film product, that the company is reaffirming its full year 2019 total revenue guidance. Full year 2019 total revenue is now expected to be at the top end of the company's guidance range of $38M-$45M. Full year 2019 revenue from the company's Suboxone franchise is expected to be at the top end of its guidance range of $29M-$32M. As of October 2019, Suboxone and the authorized generic buprenorphine-naloxone film continue to retain approximately 75% of the market for film treatments of opioid dependence, of which a substantial majority of its retained market share is branded Suboxone.

Read more at:
https://thefly.com/landingPageNews.php?id=2975849

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist